Live Breaking News & Updates on Biospace

Stay informed with the latest breaking news from Biospace on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Biospace and stay connected to the pulse of your community

BioSpace Announces 2024 Best Places to Work in Biopharma Winners

/PRNewswire/ -- BioSpace, the leader in biopharma news and careers has published its 2024 Best Places to Work list. The list includes 60 employers with U.S....

Iowa , United-states , Prnewswire-biospace , Eli-lilly , Vertex-pharmaceuticals , Alnylam-pharmaceuticals , Amgen , Best-places , Best-place , Tessera-therapeutics , Sana-biotechnology , Eikon-therapeutics

BioSpace Names Most Promising New Biopharma Companies to Watch in 2023

/PRNewswire/ -- BioSpace, the leading life sciences news and careers site, has announced its 2023 selections for the industry's most promising up-and-coming...

Iowa , United-states , Josh-goodwin , Prnewswire-biospace , Umoja-biopharma , Nextgen-bio , Seismic-therapeutic-inc , Amgen , Idrx-inc , Chroma-medicine-inc , Septerna-inc , Triana-biomedicines-inc

Monkeypox Outbreak Result Of Ignoring Early Warning Signs, Say Experts. Read Here

Nigeria had sought global help beginning in 2017 for an unprecedented outbreak of monkeypox virus, which continues to this day, with the country detecting 558 suspected cases

Nigeria , Hyundai-bioscience , Niclosamide , Siga-technologies-tecovirimat , Biospace , Gene-sequencing , Chikwe-ihekweazu , Monkeypox-latest-update , Monkeypox-virus , What-is-monekypox , Shouldi-be-worried-about-monkeypox

BioSpace Publishes 2022 US Life Sciences Salary Report, Noting Accelerating Salary Growth Compared to Previous Years

/PRNewswire/ -- BioSpace, the leader in biopharma news and careers has today published it's 2022 U.S. Life Sciences Salary Report. The report demonstrates...

Iowa , United-states , Josh-goodwin , Prnewswire-biospace , Us-life-sciences-salary , Biospace-salary , Sciences-salary , Sciences-salary-report , Salary-survey , Biospace-salary-survey , Biospace ,

Vaccine Mandates Survey Reveals Discordant Views May Fuel Challenges in Tight Labor Market

/PRNewswire/ -- BioSpace, the leader in biopharma news and careers today released a report that found 80% of unvaccinated respondents would resign if their...

United-states , Iowa , Vaccine-mandates , Biospace ,

Vaccine Mandates Survey Reveals Discordant Views May Fuel Challenges in Tight Labor Market

/PRNewswire/ -- BioSpace, the leader in biopharma news and careers today released a report that found 80% of unvaccinated respondents would resign if their...

United-states , Iowa , Vaccine-mandates , Biospace ,

NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Published: Apr 12, 2021
SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This is the third approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy.

Guangzhou , Guangdong , China , Shanghai , United-states , Renji , Henan , Suzhou , Jiangsu , Beijing , Maryland , Peking

Gluten Tolerance Test Kits Market: Increase in Prevalence of Celiac Disease to Drive the Market

Gluten Tolerance Test Kits Market: Increase in Prevalence of Celiac Disease to Drive the Market - read this article along with other careers information, tips and advice on BioSpace

United-states , Canada , America , Cerascreen-gmb , Rohit-bhisey , Celiac-disease-foundation , Custom-research , Drug-administration , National-institute-for-health , Immuno-laboratories-inc , Transparency-market-research , Glutenostics-inc

BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions

BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions - read this article along with other careers information, tips and advice on BioSpace

California , United-states , San-diego , Oregon , Bio-pharma , Paul-roben , Michelle-franklin , Neil-kumar , University-of-california , Roswell-park-comprehensive-cancer-center , Nasdaq , Bridgebio-pharma-inc

Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research

Published: Apr 13, 2021
MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) --
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Blake Aftab, Ph.D., as Vice President of Research. Dr. Aftab will lead Adicet’s research group and will further develop existing and new opportunities for the Company’s gamma delta T cell platform.
“We are very excited to have Blake join Adicet, and lead our research team as we advance the clinical development of ADI-001 and rapidly develop a deep pipeline of “off-the-shelf” gamma delta T cell therapies,” said Stewart Abbot, Chief Scientific and Operating Officer of Adicet. “Blake has committed his career, with notable success, to researching and developing cell therapies across a variety of indications including oncology, infectious disease, and autoimmune conditions, while also building strong associations with academic and industry leaders. His expertise in the allogeneic T cell therapy landscape will further enable Adicet to advance its product candidates into the clinic and expand its pipeline of ‘off-the-shelf’ gamma delta T cell product candidates.”

Boston , Massachusetts , United-states , California , San-francisco , Santa-barbara , Janhavi-mohite , Blake-aftab , Anne-bowdidge , Adicet-bio-inc , Atara-biotherapeutics-inc , University-of-california